We are live on ! Find out more

Tonix Pharmaceuticals

TNXP

Market cap $204M

11.87 USD

-0.41

3.34%

At close Updated Sep 11, 4:00 PM EDT

Pre-market

After hours

11.85

-0.02

0.17%

1 day

-3.34%

5 days

-10.75%

1 month

-3.81%

3 months

11.46%

6 months

-15.09%

Year to date

-28.28%

1 year

-61.97%

5 years

-100%

10 years

-100%

About: Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

Employees: 142

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 28.6%

Neutral 71.4%

Negative 0%

Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears

Tonix Pharmaceuticals NASDAQ: TNXP CEO Seth Lederman told attendees at the Cantor Healthcare Conference that the company's near-term focus is the commercial launch of TONMYA, its FDA-approved treatment for fibromyalgia in adults, while it advances development programs in Lyme disease prevention and transplant rejection.

Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears

Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer

BERKELEY HEIGHTS, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced the promotion of Thomas Englese to Chief Commercial Officer, effective immediately.

Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer

Tonix Pharmaceuticals to Participate in Cantor's 2026 Global Healthcare Conference

BERKELEY HEIGHTS, N.J., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced that the management team will participate in a fireside chat and 1x1s at Cantor's 2026 Global Healthcare Conference, being held September 9-11, 2026, in New York.

Tonix Pharmaceuticals to Participate in Cantor's 2026 Global Healthcare Conference

Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline

Tonix Pharmaceuticals NASDAQ: TNXP is focusing its near-term strategy on the commercial launch of TONMYA for fibromyalgia while advancing development programs in Lyme disease prevention and major depressive disorder, Chief Executive Officer Seth Lederman said during a Canaccord Genuity conference presentation.

Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline

Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript

Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript

Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript

Tonix Pharmaceuticals Q2 Earnings Call Highlights

Tonix Pharmaceuticals NASDAQ: TNXP reported second-quarter 2026 net product revenue of approximately $13.5 million, led by $11 million in sales of fibromyalgia treatment Tonmya. The company said Tonmya sales rose 197% from the first quarter, its second full quarter of commercial sales following the product's November launch.

Tonix Pharmaceuticals Q2 Earnings Call Highlights

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter Commercial and government payer coverage for TONMYA meaningfully expanded, now reaching approximately 136 million covered lives (43% of total U.S. lives) First patient enrolled in Phase 2 HORIZON study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of major depressive disorder (MDD) Phase 2 adaptive field study of TNX-4800 for the prevention of Lyme disease in the U.S. on track to start in the first quarter of 2027 pending final FDA review and agreement on study protocol Approximately $176.2 million in cash and cash equivalents as of June 30, 2026 Conference call today at 8:30 a.m. ET BERKELEY HEIGHTS, N.J.

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences

BERKELEY HEIGHTS, N.J., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biotechnology company, today announced that the management team will participate in two upcoming investor conferences in August and September 2026.

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences

Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.

Alignment with FDA on key elements of the study design support planned start of the Phase 2 study in the first quarter of 2027

Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.

Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026

BERKELEY HEIGHTS, N.J., July 27, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biotechnology company, today announced that it will host a conference call and webcast to report second quarter 2026 financial results and operational highlights on Monday, August 10, 2026, at 8:30 a.m. ET.

Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026

See News Rankings

Price charts implemented using Lightweight Charts™